Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients (AERODUO-2)
Randomized, Double-Blind, Placebo-Controlled, 14-Day Treatment, 2-Period Crossover Trial Evaluating the Lung Function Response After Treatment With Inhaled LABA and LAMA Monotherapies and Their Combination AERO-007 Administered Via Nebulization in Participants With Chronic Obstructive Pulmonary Disease (COPD) (AERODUO-2 Trial)
This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Combination of a long-acting beta-agonist (LABA) bronchodilator and a long-acting muscarinic antagonist (LAMA) bronchodilator is the preferred choice for initial therapy for patients with chronic obstructive pulmonary disease (COPD). Although there are currently multiple LABA+LAMA combination bronchodilators available in metered dose inhalers (MDIs), dry powder inhalers (DPI), and soft mist inhalers (SMI), a significant percentage of COPD patients, generally high risk and older patients, do not receive optimal benefit from inhalers.
Nebulized delivery provides an effective alternative where disease management is sub optimal. To date there are no approved LABA+LAMA combinations available by nebulization.
AERO-007 is a propriety inhalation solution formulation of fixed-dose combination of LABA+LAMA (indacaterol, AERO-001 and glycopyrrolate, AERO-002) for delivery in a general purpose nebulizer device. A phase 2a, single-dose, dose-ranging study of AERO-007 has been completed in participants with COPD at two dose levels (100/50 µg and 200/100 µg). AERO-007 at both low and high doses was well tolerated with robust, clinically meaningful and statistically significant bronchodilation with rapid onset of action that was sustained for 24 hours.
The objective of this phase 2b study is to determine the optimal doses of the monotherapy components of AERO-007 and to assess the safety, PK and bronchodilation profile of AERO-007 following 14 days of dosing in participants with COPD.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Study Director Medical Director
- Telefonnummer: +1-858-750-4717
- E-Mail: info@aerorxtherapeutics.com
Studienorte
-
-
-
London, Vereinigtes Königreich
- Rekrutierung
- Parexel
-
Manchester, Vereinigtes Königreich
- Rekrutierung
- Medicines Evaluation Unit
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Male or female aged 40 to 75 years, inclusive, at the time of informed consent
-
Clinical diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Report, 2026 for at least 12 months prior to Screening Visit 1
-
Post-bronchodilator spirometry (after 10 to 30 minutes following 4 puffs of albuterol via MDI with a spacer) at Screening Visit 2 demonstrating the following:
- FEV1 > 40 and < 80% of predicted normal (using the Global Lung Function Initiative [GLI] 2012 reference values)
- FEV1/forced vital capacity (FVC) ratio < 0.70
- ≥ 150 mL increase from pre-bronchodilator FEV1 following 4 puffs of albuterol
-
Ability to change current COPD therapy and discontinue long-acting bronchodilators, if applicable, for the duration of the trial and short-acting bronchodilators for 8 hours prior to dosing at each Treatment Visit
-
Current or former-smokers with at least 10 pack-year smoking history (eg, at least 1 pack/day for 10 years, 10 packs/day for 1 year)
-
Ability to perform reproducible spirometry according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines
-
Female participants of childbearing potential must not be pregnant, breast feeding or lactating and heterosexual female participants of childbearing potential must agree to use, with their partner, a male condom plus an approved method of highly effective birth control from the time of informed consent and for 30 days following the last administered dose
-
Female participants of childbearing potential must have a negative serum or urine pregnancy test at Screening Visit 1 and a negative urine pregnancy test prior to dosing at each Treatment Visit
-
Male participants who are sexually active with a female partner of childbearing potential must use, with their partner, a male condom plus an approved method of highly effective contraception from the time of informed consent and for 30 days following the last administered dose
-
Participants must agree not to donate semen or ova/oocytes from the time of informed consent and for 30 days following the last administered dose
-
Willing and able to provide written informed consent
Exclusion Criteria:
- Current evidence or recent history of significant comorbidities; including cardiovascular disease (such as myocardial infarction, cardiac failure, uncontrolled hypertension, or life-threatening arrhythmias), uncontrolled diabetes, neurologic, psychiatric, hepatic, renal, immunological, or hematological conditions within the last 6 months prior to Screening Visit 1
- Positive serum hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) type 1 and/or 2 antibodies at Screening Visit 1
- Lower respiratory tract infection within 6 weeks prior to Screening Visit 1
- Recent history of hospitalization due to an exacerbation of airway disease or acute worsening of COPD requiring antibiotic or systemic corticosteroid treatment within 6 months prior to Screening Visit 1
- Other respiratory disorders: Current diagnosis of predominant asthma, lung cancer, bronchiectasis, interstitial lung disease, tuberculosis, pulmonary hypertension, or other non-specific pulmonary diseases
- Prior lung volume reduction surgery or history of chest/lung irradiation
- Daily oxygen therapy for > 12 hours per day
- Body mass index >35 kg/m2
- Abnormal and clinically significant 12-lead ECG findings at Screening Visit 1
- Current or recent history of medical conditions that are contraindicated for use of an inhaled LAMA (such as urinary retention or bladder neck obstruction type symptoms, prostatic hypertrophy, or narrow-angle glaucoma) within the last 6 months prior to Screening Visit 1
- Current or recent history (previous 12 months) of excessive use or abuse of alcohol (males >21 units per week and females >14 units per week)
- Current evidence or history (within the past 2 years) of abusing legal drugs or use of illegal drugs or substances
- Donation of 450 mL of blood within 8 weeks of Screening Visit 1
- Major surgery (requiring general anaesthesia) within 6 weeks prior to Screening Visit 1, or planned surgery through the EOS Visit
- History of malignancy of any organ system, except for localized skin cancers, within 5 years prior to Screening Visit 1
- History of intolerance or hypersensitivity to any of the ingredients in the formulation for AERO-001, AERO-002, AERO-007, or other aerosol medications
- Participation in another investigational drug trial within 30 days of the last dose, 5 half-lives or twice the duration of the biological effect, whichever is longer, prior to Screening Visit 1
- History or high risk of noncompliance with trial visits and procedures or unsuitable for entry into the trial at the discretion of the Investigator
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Fakultätszuweisung
- Maskierung: Verdreifachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
|
Double-blind |
|
Experimental: Aero-001 niedrige Dosis
|
Double-blind |
|
Experimental: Aero-001 hohe Dosis
|
Double-blind |
|
Experimental: Aero-002 niedrige Dosis
|
Double-blind |
|
Experimental: Aero-002 hohe Dosis
|
Double-blind |
|
Experimental: AERO-001 medium dose
|
Double-blind |
|
Experimental: AERO-002 medium dose
|
Double-blind |
|
Experimental: AERO-007
|
Double-blind |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Bronchodilation - FEV1
Zeitfenster: Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
|
Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
|
|
Bronchodilation - FEV AUC
Zeitfenster: Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
|
Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
|
|
Bronchodilation - Peak FEV1
Zeitfenster: Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
|
Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
|
|
Bronchodilation - time to onset of FEV1 >100mL
Zeitfenster: Change in FEV1 >100mL from pre-dose on Days 1 and 14
|
Change in FEV1 >100mL from pre-dose on Days 1 and 14
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pharmacokinetics - Cmax
Zeitfenster: 0-24 hours on Days 1 and 14
|
Cmax (maximum plasma concentration) |
0-24 hours on Days 1 and 14
|
|
Pharmacokinetics - AUC
Zeitfenster: AUC(0-6 hours) on Days 1 and 14
|
AUC (area under the plasma concentration) |
AUC(0-6 hours) on Days 1 and 14
|
|
Pharmacokinetics - Tmax
Zeitfenster: Tmax on Days 1 and 14
|
Tmax (time to maximum concentration) |
Tmax on Days 1 and 14
|
|
Treatment-emergent adverse events (TEAEs)
Zeitfenster: Up to approximately Day 14
|
Number of participants with TEAEs |
Up to approximately Day 14
|
|
Blood Pressure
Zeitfenster: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in Blood Pressure |
Up to approximately Day 14
|
|
Heart Rate
Zeitfenster: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in Heart Rate |
Up to approximately Day 14
|
|
12-lead ECG - QT Interval corrected for Heart Rate Using Fridericia's Formula (QTcF)
Zeitfenster: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in QTcF |
Up to approximately Day 14
|
|
Clinical laboratory - Hematology
Zeitfenster: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in hematology parameters |
Up to approximately Day 14
|
|
Clinical laboratory - Blood Chemistry
Zeitfenster: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in blood chemistry parameters |
Up to approximately Day 14
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- AERO-007-02
- 2026-527150-39 (EudraCT-Nummer)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .